The upcoming NCI CAP-IT Summit is set to convene a diverse mix of participants, including senior leaders, experts, and emerging talents such as junior investigators and trainees, all dedicated to the fields of cancer prevention and interception.
During the summit, presenters will thoroughly assess the present landscape of both clinical and preclinical research in this domain. They will also pinpoint critical challenges and opportunities that could pave the way for the clinical application of precision methods in cancer prevention and interception.
On This Page
- All Heading 2s will automatically be pulled in to this list.
- Do not edit the content on this template.
Registration
Registration is mandatory.
Registration deadline: March 26, 2026
About the CAP-IT Program
The Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) was launched by National Cancer Institute to undertake collaborative research with the overarching goal of discovering molecularly or immunologically targeted agents for cancer prevention and interception.
CAP-IT seeks to establish a new discovery research paradigm in cancer prevention that leverages the potential oncotarget leads identified from precancer biology research and related databases and exploits their oncogenic characteristics and vulnerabilities to discover innovative cancer prevention-interception agents especially focusing on higher-risk populations.
The ultimate goals of CAP-IT are to advance newly discovered efficacious cancer preventive or interceptive agents to the existing NCI, Division of Cancer Prevention preclinical and clinical development pipelines,PREVENT Program, for further development towards IND and Cancer Prevention Clinical Trials Network (CP-CTNet) for early phase clinical trials for fast-tracking agent discovery and development for cancer prevention and interception from bench to bedside.
For more information on CAP-IT please
- Visit: NCI CAP-IT Program
or - Email: CAP-IT@nih.gov